In This Article:
Whilst it may not be a huge deal, we thought it was good to see that the Starpharma Holdings Limited (ASX:SPL) Non-Executive Director, Jeff Davies, recently bought AU$80k worth of stock, for AU$0.091 per share. While that isn't the hugest buy, it actually boosted their shareholding by 1,759%, which is good to see.
Check out our latest analysis for Starpharma Holdings
The Last 12 Months Of Insider Transactions At Starpharma Holdings
Notably, that recent purchase by Jeff Davies is the biggest insider purchase of Starpharma Holdings shares that we've seen in the last year. So it's clear an insider wanted to buy, at around the current price, which is AU$0.094. That means they have been optimistic about the company in the past, though they may have changed their mind. While we always like to see insider buying, it's less meaningful if the purchases were made at much lower prices, as the opportunity they saw may have passed. The good news for Starpharma Holdings share holders is that insiders were buying at near the current price.
While Starpharma Holdings insiders bought shares during the last year, they didn't sell. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!
Starpharma Holdings is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this free list of growing companies with recent insider purchasing, could be just the ticket.
Insider Ownership Of Starpharma Holdings
Many investors like to check how much of a company is owned by insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Based on our data, Starpharma Holdings insiders have about 4.2% of the stock, worth approximately AU$1.6m. We consider this fairly low insider ownership.
So What Does This Data Suggest About Starpharma Holdings Insiders?
The recent insider purchases are heartening. And the longer term insider transactions also give us confidence. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. While the overall levels of insider ownership are below what we'd like to see, the history of transactions imply that Starpharma Holdings insiders are reasonably well aligned, and optimistic for the future. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. For instance, we've identified 2 warning signs for Starpharma Holdings (1 is significant) you should be aware of.